Codeine, alone and with paracetamol (acetaminophen), for cancer pain

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Straube, Carmen ^a   Derry, Sheena ^b   Jackson, Kenneth C ^c   Wiffen, Philip J ^b   Bell, Rae F ^d   Strassels, Scott ^e   Straube, Sebastian ^f  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c WINGATE UNIVERSITY   (United States)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e Healthcare Policies and Economic Outcomes   (United States)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCLOFENAC; ANALGESIC AGENT; BENZOPYRANOPERIDINE; CIRAMADOL; CODEINE; DRONABINOL; HYDROCODONE; IBUPROFEN; KETOROLAC TROMETAMOL; MORPHINE; OXYCODONE; PARACETAMOL; PIROXICAM; PLACEBO; TETRAHYDROCANNABINOL; TRAMADOL; UNCLASSIFIED DRUG; VIMINOL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ANALGESIC ACTIVITY; CANCER PAIN; CONSTIPATION; DEATH; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; NAUSEA; NUMERIC RATING SCALE; PAIN INTENSITY; PAIN SEVERITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; VISUAL ANALOG SCALE; VOMITING; ADULT; ADVERSE EFFECTS; COMPLICATION; DRUG COMBINATION; NEOPLASM; PAIN; PROCEDURES;

ACETAMINOPHEN; ADULT; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; CODEINE; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942814892     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006601.pub4     Document Type: Review

References (77)

1. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. Journal of Pharmacology and Experimental Therapeutics 1978;207(1):92-100.
2. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. Journal of Pharmacology and Experimental Therapeutics 1978;207(1):101-8.
3. Capretti G, Frigerio G. Controlled clinical study of the analgesic activity of a new drug (Z. 424) in pain caused by neoplasms [Studio clinico controllato dell'attivita analgesica di un nuovo farmaco (Z. 424) nel dolore da neoplasie]. La Clinica Terapeutica 1970;52(4):361-9.
4. Carlson RW, Borrison RA, Sher HB, Eisenberg PD, Mowry PA, Wolin EM. A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Pharmacotherapy 1990;10(3):211-6.
5. Chen Y, Zhu W, Liang H, Wu G. The analgesic effect of ibuprofen-codeine sustained release tablets on postoperative and cancer pain. Chinese Journal of Clinical Rehabilitation 2003;7(8):1290-1.
6. Dhaliwal HS, Sloan P, Arkinstall WW, Thirlwell MP, Babul N, Harsanyi Z, et al. Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. Journal of Pain and Symptom Management 1995;10(8):612-23.
7. Jochimsen PR, Lawton RL, VerSteeg K, Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology and Therapeutics 1978;24(2):223-7.
8. Moertel CG, Ahmann DL, Taylor WF, Schwartau N. Aspirin and pancreatic cancer pain. Gastroenterology 1971;60(4):552-3.
9. Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology and Therapeutics 1975;18(1):84-9.
10. Rico MA, Cura MA, Harbst H, Palominos A, Figueroa M, Kramer V. Assessment of tramadol as an alternative opioid instead of codeine at the second step of the WHO analgesic scale [Evaluación de tramadol como un opioide alternativoa la codeína en el segundo peldaño de la escalera analgésica de la OMS]. Revista de la Sociedad Espanola del Dolor 2000;7:345-53.
11. Rodriguez RF, Bravo LE, Castro F, Montoya O, Castillo JM, Castillo MP, et al. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. Journal of Palliative Medicine 2007;10(1):56-60.
12. Rodriguez RF, Castillo JM, Castillo MP, Montoya O, Daza P, Rodríguez MF, et al. Hydrocodone/acetaminophen and tramadol chlorhydrate combination tablets for the management of chronic cancer pain: a double-blind comparative trial. Clinical Journal of Pain 2008;24(1):1-4. [DOI: 10.1097/AJP.0b013e318156ca4d]
13. Rodriguez RF, Castillo JM, Del Pilar Castillo M, Nuñez PD, Rodriguez MF, Restrepo JM, et al. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study. Clinical Therapeutics 2007;29(4):581-7.
14. Stambaugh JE Jr, McAdams J. Comparison of the analgesic efficacy and safety oral ciramadol, codeine, and placebo in patients with chronic cancer pain. Journal of Clinical Pharmacology 1987;27(2):162-6.
15. Staquet M, Luyckx A, Van Cauwenberge H. A double-blind comparison of alclofenac, pentazocine, and codeine with placebo control in pathologic pain. Journal of Clinical Pharmacology and New Drugs 1971;11(6):450-5.
16. Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology and Therapeutics 1978;23(4):397-401.
17. Staquet M, Renaud A. Double-blind randomized trial of piroxicam and codeine in cancer pain. Current Theraputics and Research 1993;53(4):435-40.
18. Chary S, Goughnour BR, Moulin DE, Thorpe WR, Harsanyi Z, Darke AC. The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. Journal of Pain and Symptom Management 1994;9(6):363-71.
19. Corgill DA, Ligon CW, Defelice EA. Double-blind comparison of namoxyrate, codeine, aspirin, and placebo. Current Therapeutic Research: Clinical and Experimental 1965;7(5):263-74.
20. De Conno F, Ripamonti C, Sbanotto A, Barletta L, Zecca E, Martini C, et al. A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. Journal of Pain and Symptom Management 1991;6(7):423-7.
21. Jochimsen PR, Noyes R Jr. Appraisal of codeine as an analgesic in older patients. Journal of the American Geriatrics Society 1978;26(11):521-3.
22. Kantor TG, Sunshine A, Laska E, Meisner M, Hopper M. Oral analgesic studies: pentazocine hydrochloride, codeine, aspirin, and placebo and their influence on response to placebo. Clinical Pharmacology and Therapeutics 1966;7(4):447-54.
23. Martinetti L, Lodola E, Monafo V, Ferrari V. Clinical evaluation of an oral analgesic, Z.424, in patients with chronic pain. Journal of Clinical Pharmacology 1970;10(6):390-9.
24. Minotti V, Patoia L, Roila F, Basurto C, Tonato M, Pasqualucci V, et al. Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam, and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain 1989;36(2):177-83.
25. Minotti V, De Angelis V, Righetti E, Celani MG, Rossetti R, Lupatelli M, et al. Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain 1998;74(2-3):133-7.
26. Mystakidou K, Katsouda E, Kouloulias V, Kouvaris J, Tsiatas M, Vlahos L. Comparison of transdermal fentanyl with codeine/paracetamol, in combination with radiotherapy, for the management of metastatic bone pain. Journal of Opioid Management 2005;1(4):2004-10.
27. Pistevou-Gompaki K, Kouloulias VE, Varveris C, Mystakidou K, Georgakopoulos G, Eleftheriadis N, et al. Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life. Current Medical Research and Opinion 2004;20(2):159-63.
28. Sniezek PJ, Brodland DG, Zitelli JA. A randomized controlled trial comparing acetaminophen, acetaminophen and ibuprofen, and acetaminophen and codeine for postoperative pain relief after Mohs surgery and cutaneous reconstruction. Dermatologic Surgery 2011;37(7):1007-13.
29. Stambaugh JE Jr. Analgesic Equivalence of Tylox® and Percodan®: double-blind crossover study of patients with pain from malignancy. Current Therapeutic Research 1980;27(2):302-8.
30. Sunshine A, Olson NZ. Analgesic efficacy of ketoprofen in postpartum, general surgery, and chronic cancer pain. Journal of Clinical Pharmacology 1988;28(12 Suppl):S47-54.
31. Watanabe S, Pereira J, Tarumi Y, Hanson J, Bruera E. A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain. Journal of Palliative Medicine 2008;11(4):570-4.
32. Bennett M, Cresswell H. Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning. Palliative Medicine 2003;17(5):418-22. [DOI: 10.1191/0269216303pm773oa]
33. Joint Formulary Committee. British National Formulary (online). www.medicinescomplete.com (Accessed on 5 March 2014). London: BMJ Group and Pharmaceutical Press.
34. Caraceni A, Hanks G, Kaasa S, Bennett M, Brunelli C, Cherny N, et al.for the European Palliative Research Collaborative (EPCRC), on behalf of the European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology 2012;13(2):e58-68. [DOI: 10.1016/S1470-2045(12)70040-2]
35. Cascarbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. European Journal of Clinical Investigation 2003;33 Suppl 2:17-22.
36. Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. New England Journal of Medicine 2009;361(8):827-8. [DOI: 10.1056/NEJMc0904266]
37. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres?. Pain 1997;72(1-2):95-7. [DOI: 10.1016/S0304-3959(97)00005-5]
38. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4. [DOI: 10.1136/bmj.310.6977.452]
39. De Conno F, Panzeri C, Brunelli C, Saita L, Ripamonti C. Palliative care in a national cancer center: results in 1987 versus 1993 versus 2000. Journal of Pain and Symptom Management 2003;25(6):499-511. [DOI: 10.1016/S0885-3924(03)00069-1]
40. Derry S, Moore RA, McQuay HJ. Single dose oral codeine, as a single agent, for acute postoperative pain in adults. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD008099.pub2]
41. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
42. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2]
43. Altman DG, Antes G, Gøtzsche P, Higgins JPT, Jüni P, Lewis S, et al. Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011.
44. Jackson KC, Lipman AG. Opioid analgesics. In: Tollison CD, Satterthwaite JR, Tollison JW editor(s). Practical Pain Management, 3rd Ed. Baltimore, MD: Lippincott, Williams, and Wilkins, 2001.
45. Jacox A, Carr DB, Payne R, Berde CB, Brietbart W, Cain JM, et al. Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, MD: Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, 1994.
46. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274:1870-3. [DOI: 10.1001/jama.1995.03530230056031]
47. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Controlled Clinical Trials 1996;17(1):1-12. [DOI: 10.1016/0197-2456(95)00134-4]
48. Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012;15 (3 Suppl):ES39-58.
49. Kuehn BM. FDA: No codeine after tonsillectomy for children. JAMA 2013;309(11):1100. [DOI: 10.1001/jama.2013.2403]
50. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33.
51. Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Canadian Family Physician 2007;53(1):33-5.
52. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD005180]
53. McQuay HJ, Moore RA. An Evidence-Based Resource for Pain Relief. Oxford: Oxford University Press, 1998.
54. Miaskowski C, Cleary J, Burney R, Coyne P, Finley R, Foster R, et al. Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guideline Series, No. 3. Glenview, IL: American Pain Society, 2005.
55. Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
56. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]
57. Moore RA, Derry S, Wiffen PJ. Challenges in design and interpretation of chronic pain trials. British Journal of Anaesthesia 2013;111(1):38-45.
58. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: BMJ Books, 1995:50-63.
59. Nicholson AB. Methadone for cancer pain. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003971.pub3]
60. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515]
61. Anon. Codeine. www.opiates.com/codeine/(Accessed 3 Jan 2014) 2013.
62. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. Journal of Pharmacology and Experimental Therapeutics 1989;251(2):477-83.
63. Health and Social Care Information Centre, Prescribing, Primary Care. Prescription Cost Analysis, England 2012. The Health and Social Care Information Centre, 2013. [ISBN: 978-1-84-636859-2]
64. Quigley C. Opioids in people with cancer-related pain. Clinical Evidence (Online) 2008;Jul 31:2408.
65. Guidance for the Use of Codeine in Children. Royal College of Anaesthetists, Association of Paediatric Anaesthetists of Great Britain and Ireland, Joint Medicines Committee of the Royal College of Paediatrics and Child Health, Neonatal and Paediatric Pharmacists Group. 2013. [: http://www.rcpch.ac.uk/system/files/protected/news/Codeine-statement-RCPCH-NPPG-RCoA-2013-11.pdf (accessed 24 April 2014)]
66. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
67. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Annals of Oncology 2012;23 (Suppl 7):vii139-54.
68. Ripamonti CI. Pain management. Annals of Oncology 2012;23 (Suppl 10):x294-x301. [DOI: 10.1093/annonc/mds360]
69. Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008.
70. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266-75. [DOI: 10.1111/j.1365-2125.2008.03200.x]
71. Toms L, Derry S, Moore RA, McQuay HJ. Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001547.pub2]
72. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Annals of Oncology 2007;18(9):1437-49. [DOI: 10.1093/annonc/mdm056]
73. Ventafridda V, Saita L, Ripamonti C, De Conno F. WHO guidelines for the use of analgesics in cancer pain. International Journal of Tissue Reactions 1985;7:93-6.
74. World Health Organization. WHO Cancer Pain Relief - a guide to opioid availability, 2nd Edition. Geneva: WHO, 1996.
75. World Health Organization. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Geneva: WHO, 2012.
76. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD003868.pub3]
77. Wittwer E, Kern SE. Role of morphine's metabolites in analgesia: concepts and controversies. The AAPS Journal 2006;8(2):E348-52. [DOI: 10.1007/BF02854905]